Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v25.i4.20
pages 347-379

Vitamin B12-Mediated Transport: A Potential Tool for Tumor Targeting of Antineoplastic Drugs and Imaging Agents

Yashwant Gupta
Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar-470 003 (MP), India
Dharm Veer Kohli
Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar (M. P.) 470003, India
Sanjay Kumar Jain
Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Central University, Sagar (M.P.), India

RÉSUMÉ

The uptake of vitamin B12 (cyanocobalamin, Cbl/VB12) in mammalian cells is mediated by specific, high-affinity receptors for the vitamin B12-binding protein, transcobalamin II, which is expressed on the plasma membrane. The receptor for vitamin B12 is overexpressed on a number of human tumors, including cancers of the ovary, kidney, uterus, testis, brain, colon, lung, and myelocytic blood cells. Furthermore, the affinity of cyanocobalamin conjugates for cell surface transcobalamin II receptors seems to be high enough so that vitamin B12 derivatization with the cytotoxic agent or carriers bearing cytotoxic drugs allows the selective delivery of diagnostic and therapeutic agents to cancer cells. Thus, conjugates of vitamin B12 enter receptor-expressing cancer cells via receptor-mediated endocytosis, and targeting may be accomplished by multiple mechanisms, depending on the drug-delivery strategy. This review summarizes the applications of vitamin B12 as a targeting ligand and highlights the various methods being developed for delivery of therapeutic and imaging agents to cancer cells in vitro and in vivo. This review reflects the potentiality of vitamin B12 for tumor targeting of chemotherapeutic and diagnostic agents.


Articles with similar content:

Steroid Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 3
Vandana Soni, Piush Khare, Suresh P. Vyas, Aviral Jain, Arvind Gulbake, Sanjay Kumar Jain, Pramod Mishra
Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 5
Min Chen, Ying Fan, Xuefeng Xia, Wen Wu, Philippe Maincent, Jinqiang Zhang
Progress in Lipid-Based Nanoparticles for Cancer Therapy
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 3-4
Eliahu Heldman, Charles Linder, Sarina Grinberg
Nano-Aggregates: Emerging Delivery Tools for Tumor Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 6
Vinod Kumar Sharma, Ankit Jain, Vandana Soni
Use of Vitamin B12 Conjugates to Deliver Protein Drugs by the Oral Route
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.15, 1998, issue 6
Gregory J. Russell-Jones